Chemotherapy versus best supportive care in stage IV non-small cell lung cancer, non metastatic to the brain

Anelli, Agnaldo; Lima, Candice A. A.; Younes, Riad Naim; Gross, Jefferson Luiz; Fogarolli, R.C.

doi:10.1590/s0041-87812001000200004

Cited by 7 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Chemotherapy in stage IV NSCLC not metastatic to the brain has been associated with significantly increased survival rates when compared to best sup-portive care. 47 Moreover, histopathologic data may help predict the chemotherapy response in small cell lung cancer. 48 Radiotherapy plays a fundamental role in the treatment of nonsmall cell lung cancer patients.…”

Section: Discussionmentioning

confidence: 99%

Nonsmall cell lung cancer: evaluation of 737 consecutive patients in a single institution

et al. 2004

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Nonsmall cell lung cancer: evaluation of 737 consecutive patients in a single institution

et al. 2004

Self Cite

View full text Add to dashboard Cite

show abstract

“…In general, the overall survival was better than in those who received chemotherapy in comparison to best support of care, but considerably lower than in those reported in the literature. 23 , 24 , 31 – 33 There are no data regarding maintenance therapy in the Brazilian population.…”

Section: Treatmentmentioning

confidence: 99%

Lung cancer in Brazil: epidemiology and treatment challenges

Sá

Coelho

Capelozzi

et al. 2016

LCTT

View full text Add to dashboard Cite

Lung cancer persists throughout the world as a major cause of death. In 2014, data from the Brazilian National Cancer Institute (INCA) estimated 16.400 new cases of lung cancer among men (second most common) and 10.930 new cases among women (fourth most common). These data are consistent for all Brazilian regions and reflect the trends of cancer in the country over the last decade. Brazil is a continental country, the largest in Latin America and fifth in the world, with an estimated population of >200 million. Although the discrepancy in the national income between rich and poor has diminished in the last 2 decades, it is still huge. More than 75% of the Brazilian population do not have private health insurance and rely on the national health care system, where differences in standard of cancer care are evident. It is possible to point out differences from the recommendations of international guidelines in every step of the lung cancer care, from the diagnosis to the treatment of advanced disease. This review aims to describe and recognize these differences as a way to offer a real discussion for future modifications and action points toward delivery of better oncology care in our country.

show abstract

“…(17) For patients with stage IIIB or IV NSCLC, chemotherapy regimens based on platinum derivatives have been shown to be beneficial in terms of survival and quality of life. (18,19) However, the treatment can have side effects and can impede the performance of activities of daily living.…”

Section: Discussionmentioning

confidence: 99%

Evolução do status de performance, índice de massa corpórea e distância percorrida no teste de caminhada de seis minutos em pacientes com câncer de pulmão avançado submetidos à quimioterapia

et al. 2010

View full text Add to dashboard Cite

Evolução do status de performance, índice de massa corpórea e distância percorrida no teste de caminhada de seis minutos em pacientes com câncer de pulmão avançado submetidos à quimioterapia Luciana Machado, Ivete Alonso Bredda Saad, Helen Naemi Honma, André Moreno Morcillo, Lair Zambon Abstract Objective: To evaluate the effect of chemotherapy on the physical condition of patients with advanced lung cancer. Methods: We evaluated 50 patients with non-small cell lung cancer (in stages IIIB and IV) and Eastern Cooperative Oncology Group (ECOG) performance status scale scores between zero and two. All patients underwent chemotherapy using paclitaxel and platinum derivatives and were evaluated at three time points (prechemotherapy, postchemotherapy and six months after starting the treatment), at which the ECOG scale, the body mass index (BMI) and the six-minute walk distance (6MWD) were assessed. Results: Of the 50 patients included in the study, 14 died, 5 were excluded due to the worsening of their performance status, and 31 completed the six-month follow-up. There was no statistically significant difference between the time points of assessment for BMI (prechemotherapy vs. postchemotherapy, p = 1.00; and prechemotherapy vs. six months later, p = 0.218) or for 6MWD. Performance status improved, and this was especially due to the increase in the number of asymptomatic patients after the six-month follow-up (p = 0.031). Conclusions: Chemotherapy had a beneficial effect on the performance status of the patients. No significant changes in BMI or 6MWD were found during the study period, which might suggest the maintenance of the physical condition of the patients. 2 ) and carboplatin (area under the curve/5 = 300-600 mg/m 2 ). The initial exclusion criteria were as follows: having previously undergone lung surgery; and presenting with brain metastasis. During the study period, patients who presented with an ECOG PS score > 2 were excluded, in accordance with the treatment protocol of our facility, where chemotherapy is not given to such patients. (7) Therefore, the only exclusion criterion adopted during the follow-up visits was presenting with an elevated ECOG PS scale score (> 2).All of the patients gave written informed consent. The study was approved by the local research ethics committee (ruling no. 209/2006).The patients were selected during medical visits to the Lung Cancer Outpatient Clinic of the State University at Campinas Hospital das Clínicas, located in the city of Campinas, Brazil.After the inclusion criteria had been applied, the patients were evaluated and data were collected.The evaluations and data collection were carried out at three time points: prechemotherapy; postchemotherapy (two weeks after the last cycle of chemotherapy); and six months after the start of treatment. The evaluation consisted of collecting personal data, determining PS, evaluating BMI, and administering the 6MWT.In order to determine the PS, we used the ECOG scale, which measures the overall functional performance of patients...

show abstract

Chemotherapy versus best supportive care in stage IV non-small cell lung cancer, non metastatic to the brain

Cited by 7 publications

References 18 publications

Nonsmall cell lung cancer: evaluation of 737 consecutive patients in a single institution

Nonsmall cell lung cancer: evaluation of 737 consecutive patients in a single institution

Lung cancer in Brazil: epidemiology and treatment challenges

Evolução do status de performance, índice de massa corpórea e distância percorrida no teste de caminhada de seis minutos em pacientes com câncer de pulmão avançado submetidos à quimioterapia

Contact Info

Product

Resources

About